|
KONDOU Shunsuke
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position |
|
| Article types | Review article |
| Language | English |
| Peer review | Peer reviewed |
| Presence of invitation | Invited paper |
| Title | Expanding indications and developmental landscape of HER2-targeted therapies in breast cancer: a pharmacotherapeutic perspective. |
| Journal | Formal name：Expert opinion on pharmacotherapy Abbreviation：Expert Opin Pharmacother ISSN code：17447666/14656566 |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | pp.2025 Nov 16 |
| Author and coauthor | Hikari Sano, Hideyuki Hayashi, Naomi Nakao, Hiroko Hosoi, Shunsuke Kondo |
| Authorship | Lead author |
| Publication date | 2025/11 |
| Summary | INTRODUCTION:This review provides an updated overview of the evolving pharmacologic landscape of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer, highlighting key clinical trial data, recent indication expansions, resistance mechanisms, and emerging therapeutic agents in development.AREAS COVERED:This review draws on a comprehensive literature search of published studies and major oncology conference proceedings, focusing primarily on data from key phase III clinical trials of HER2-targeted therapies. Studies published within the past decade that have influenced current standards of care were prioritized.EXPERT OPINION:The treatment paradigm for HER2-expressing breast cancer is evolving rapidly. Trastuzumab deruxtecan has redefined management for both HER2-positive and the newly recognized HER2-low subgroups, while tucatinib offers a critical systemic option for central nervous system metastases. Optimal sequencing and resistance management remain critical challenges in this dynamic field. Nonetheless, HER2-targeted pharmacotherapy continues to advance rapidly, driven by innovative drug designs and strategic clinical developments. |
| DOI | 10.1080/14656566.2025.2591813 |
| PMID | 41243354 |